<?xml version='1.0' encoding='utf-8'?>
<document id="24410514"><sentence text="Drug-drug interaction with statins." /><sentence text="3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase inhibitors (the so-called statins: atorvastatin, fluvastatin, pravastatin, lovastatin, rosuvastatin and simvastatin) are a well-established class of drugs in the treatment of hypercholesterolemia"><entity charOffset="0-37" id="DDI-PubMed.24410514.s2.e0" text="3-hydroxy-3-methyl-glutaryl (HMG)-CoA" /><entity charOffset="83-95" id="DDI-PubMed.24410514.s2.e1" text="atorvastatin" /><entity charOffset="97-108" id="DDI-PubMed.24410514.s2.e2" text="fluvastatin" /><entity charOffset="110-121" id="DDI-PubMed.24410514.s2.e3" text="pravastatin" /><entity charOffset="123-133" id="DDI-PubMed.24410514.s2.e4" text="lovastatin" /><entity charOffset="135-147" id="DDI-PubMed.24410514.s2.e5" text="rosuvastatin" /><entity charOffset="152-163" id="DDI-PubMed.24410514.s2.e6" text="simvastatin" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e0" e2="DDI-PubMed.24410514.s2.e0" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e0" e2="DDI-PubMed.24410514.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e0" e2="DDI-PubMed.24410514.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e0" e2="DDI-PubMed.24410514.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e0" e2="DDI-PubMed.24410514.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e0" e2="DDI-PubMed.24410514.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e0" e2="DDI-PubMed.24410514.s2.e6" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e1" e2="DDI-PubMed.24410514.s2.e1" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e1" e2="DDI-PubMed.24410514.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e1" e2="DDI-PubMed.24410514.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e1" e2="DDI-PubMed.24410514.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e1" e2="DDI-PubMed.24410514.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e1" e2="DDI-PubMed.24410514.s2.e6" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e2" e2="DDI-PubMed.24410514.s2.e2" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e2" e2="DDI-PubMed.24410514.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e2" e2="DDI-PubMed.24410514.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e2" e2="DDI-PubMed.24410514.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e2" e2="DDI-PubMed.24410514.s2.e6" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e3" e2="DDI-PubMed.24410514.s2.e3" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e3" e2="DDI-PubMed.24410514.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e3" e2="DDI-PubMed.24410514.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e3" e2="DDI-PubMed.24410514.s2.e6" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e4" e2="DDI-PubMed.24410514.s2.e4" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e4" e2="DDI-PubMed.24410514.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e4" e2="DDI-PubMed.24410514.s2.e6" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e5" e2="DDI-PubMed.24410514.s2.e5" /><pair ddi="false" e1="DDI-PubMed.24410514.s2.e5" e2="DDI-PubMed.24410514.s2.e6" /></sentence><sentence text=" Statin monotherapy is generally well tolerated, with a low frequency of adverse events" /><sentence text=" The most important adverse effects associated with statins are myopathy and an asymptomatic increase in hepatic transaminases, both of which occur infrequently" /><sentence text=" Since statins are prescribed on a long-term basis, possible interactions with other drugs deserve particular attention, as many patients will typically receive pharmacological therapy for concomitant conditions during the course of statin treatment" /><sentence text=" Moreover, a combination of therapy between statins and other classes of lipid-lowering agents (e" /><sentence text="g" /><sentence text=", ezetimibe, fibrates, resins and nicotinic acid) is recommended for some patients by current guidelines"><entity charOffset="2-11" id="DDI-PubMed.24410514.s8.e0" text="ezetimibe" /><entity charOffset="13-21" id="DDI-PubMed.24410514.s8.e1" text="fibrates" /><entity charOffset="34-48" id="DDI-PubMed.24410514.s8.e2" text="nicotinic acid" /><pair ddi="false" e1="DDI-PubMed.24410514.s8.e0" e2="DDI-PubMed.24410514.s8.e0" /><pair ddi="false" e1="DDI-PubMed.24410514.s8.e0" e2="DDI-PubMed.24410514.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24410514.s8.e0" e2="DDI-PubMed.24410514.s8.e2" /><pair ddi="false" e1="DDI-PubMed.24410514.s8.e1" e2="DDI-PubMed.24410514.s8.e1" /><pair ddi="false" e1="DDI-PubMed.24410514.s8.e1" e2="DDI-PubMed.24410514.s8.e2" /></sentence><sentence text=" Therefore, the potential for drug-drug interactions emerges as a relevant factor in determining the safety profile of statins" /><sentence text=" This review summarizes the pharmacokinetic properties of statins and emphasizes their clinically relevant drug interactions" /><sentence text=" " /></document>